Clinical Trial Goal
To find out if the combination of blinatumomab and ponatinib is safe and works well to treat Ph+ ALL
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following:
- Ph+ ALL
- Lymphoid accelerated or blast phase chronic myeloid leukemia (CML)
- ALL with MRD
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Blinatumomab is a bispecific T cell engager (BiTE) antibody that targets CD19 on certain cells.
Ponatinib is a small molecule inhibitor (also called a tyrosine kinase inhibitor, or TKI). It blocks BCR-ABL in certain cells.
You’ll get treatment in cycles that last 6 weeks. For 5 cycles, you'll get:
Ponatinib is a small molecule inhibitor (also called a tyrosine kinase inhibitor, or TKI). It blocks BCR-ABL in certain cells.
You’ll get treatment in cycles that last 6 weeks. For 5 cycles, you'll get:
- Blinatumomab – Given as a continuous intravenous (IV) infusion for 4 weeks. The drug is given by a small pump that you’ll carry with you the whole time. You’ll get a shoulder bag or belt bag that holds the pump and the drug. You will be able to wear regular clothes, walk around, and perform normal daily activities.
- Cytarabine - Given through a needle in your lower back (lumbar puncture) every other week for the first 4 cycles
- Methotrexate - Given through a needle in your lower back (lumbar puncture) every other week for the first 4 cycles
- Ponatinib – A pill that you take by mouth 1 time each day
You may continue treatment with ponatinib for as long as the clinical trial doctors think it's best for your health. After you finish treatment, the clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has approved blinatumomab and ponatinib to treat some types of leukemia. Using these drug together to treat Ph+ ALL in older adults is new and unproven.
Locations
M D Anderson Cancer CenterRECRUITING
Houston, Texas
Elias Jabbour, 713-792-4764, ejabbour@mdanderson.org
Sponsors
collaborator: National Cancer Institute (NCI), collaborator: Amgen, collaborator: Takeda, lead: M.D. Anderson Cancer Center

